월스트리트의 반응에도 불구하고 의사들이 모더나와 머크의 암 백신 데이터를 주요 진전으로 평가

Medical specialists have identified the recent vaccine results from Moderna and Merck as a major breakthrough for melanoma patients. While the clinical data suggests a significant advancement in cancer treatment, the stock market reaction has been relatively subdued. The vaccine is designed to target melanoma following surgical intervention to prevent recurrence. This development highlights the growing intersection of biotechnology and personalized medicine. Investors are now closely watching how these clinical successes translate into long-term commercial viability.